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Background:Microﬂuidic devices recreate the hemodynamic conditions of thrombosis.
Methods:Whole blood inhibited with PPACK was treated ex vivo with inhibitors and perfused over collagen for
300 s (wall shear rate = 200 s-1) using amicroﬂuidic ﬂow assay. Platelet accumulationwasmeasured in the pres-
ence of COX-1 inhibitor (aspirin, ASA), P2Y1 inhibitor (MRS 2179), P2Y12 inhibitor (2MeSAMP) or combined P2Y1
and P2Y12 inhibitors.
Results: High dose ASA (500 μM), 2MeSAMP (100 μM), MRS 2179 (10 μM), or combined 2MeSAMP andMRS 2179
decreased total platelet accumulation by 27.5%, 75.6%, 77.7%, and 87.9% (p b 0.01), respectively. ASA reduced sec-
ondary aggregation rate between 150 and 300 s without effect on primary deposition rate on collagen from 60 to
150 s. In contrast, 2MeSAMP and MRS 2179 acted earlier and reduced primary deposition to collagen between 60
and 105 s and secondary aggregation between 105 and 300 s. RCOX and RP2Y (deﬁned as a ratio of secondary aggre-
gation rate to primary deposition rate) demonstrated 9 of 10 subjects had RCOX b 1 or RP2Y b 1 following ASA or
2MeSAMP addition, while 6 of 10 subjects had RP2Y b 1 following MRS 2179 addition. Combined MRS 2179 and
2MeSAMP inhibited primary platelet deposition rate and platelet secondary aggregation beyond that of each indi-
vidual inhibitor. Receiver-Operator Characteristic area under the curve (AUC) indicated the robustness of RCOX
and RP2Y to detect inhibition of secondary platelet aggregation by ASA, 2MeSAMP, and MRS 2179 (AUC of 0.874
0.966, and 0.889, respectively).
Conclusions:Microﬂuidic devices can detect platelet sensitivity to antiplatelet agents. The R-value can serve as a self-
normalized metric of platelet function for a single blood sample.© 2013 Elsevier Ltd. All rights reserved.Introduction
Antiplatelet therapies are used in a variety of clinical settings from
management of unstable angina to risk reduction ofmyocardial infarction
or stroke. Aspirin is used by over 50 million patients in the United States
to reduce the risk of cardiovascular events [1]. Aspirin irreversibly acety-
lates serine 529of cyclooxygenase-1 (COX-1), blocking the enzymeactive
site for arachidonic acid and inhibiting the generation of prostaglandinH2
and thus thromboxaneA2 (TXA2) production fromplatelets [2]. Inhibition
of platelet TXA2 synthesis prevents platelet activation through the TXA2
receptor (TP), a receptor encoded by the TBXA2R gene.
In addition to TXA2, adenosine disphosphate (ADP) receptors are an-
other target of antiplatelet therapies. The platelet plasmamembrane con-
tains two ADP receptors, P2Y1 and P2Y12, which are purinergic G protein
coupled receptors. P2Y1 is linked to Gq and ADP signaling through this
pathway results in rapid Ca2+ mobilization and platelet shape change
[3,4]. P2Y12 is linked to a Gi protein. ADP binding to P2Y12 inhibitsse 1; (TXA2), thromboxane A2;
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ghts reserved.adenylate cyclase and stabilizes secondary platelet aggregation. Current
therapies that target the P2Y12 receptor vary fromprodrugs that irrevers-
ibly antagonize the P2Y12 receptor to direct, reversible antagonists [4,19].
Thienopyridines clopidogrel and prasugrel are examples of the former,
while ticagrelor is an example of the latter. Currently, no P2Y1 antagonists
are on themarket, however, combined P2Y1 and P2Y12 antagonists are in
development [4,5]. To mimic the action of P2Y1 and P2Y12 antiplatelet
therapies ex vivo, 2'-deoxy-N6-methyl adenosine 3',5'-diphosphate
(MRS 2179) and 2-methylthioadenosine 5-monophosphate (2MeSAMP)
are used in this study as highly selective P2Y1 and P2Y12 antagonists,
respectively.
Targeting signaling pathways such as TXA2 production and ADP/
P2Y12 signaling reduces secondary platelet aggregationwhile not severe-
ly altering primary haemostasis. However, the delicate balance between
preventing excessive clotting and increasing bleeding risks requires care-
ful monitoring of antiplatelet therapies. The evaluation of the effect of
pharmacological agents on platelet function often rely on tests with
poorly deﬁned ﬂuid mechanics and ﬂow ﬁelds (eg. aggregometry) that
fail to replicate platelet adhesivemechanisms under realistic and deﬁned
hemodynamic conditions. Underﬂowconditions, the efﬁcacyof pharma-
cological agents greatly depend on granule release, platelet-platelet con-
tacts, and convective removal of autocrinic agonists from the injury site.
Fig. 1. 8-channel microﬂuidic device, measured platelet ﬂuorescence dynamics, and RCOX,
RP2Y schematic summaries. (A), Photograph of the 8-channel microﬂuidic device, the de-
vice is fed by 8 wells converging to a single outlet. (B), Platelet ﬂuorescence values over
time in the presence of aspirin, 2MeSAMP, andMRS 2179. Error bars indicate standard de-
viation from6measurements at each time point. (C), Graphic representation of RCOX based
on a ratio of deposition rates (F') of secondary platelet aggregation to initial platelet adhe-
sion to collagen. (D), Graphic representation of RP2Y.
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to study anti-platelet agents. These devices offer spatially controlled focal
injuries with collagen or collagen with tissue factor bearing surfaces
[6–8]. Microﬂuidic devices have also been used to study clot contraction
and clot permeability with precise control of wall shear stress and
transthrombus pressure gradients [8,10]. In fact, the core-shell hierarchy
of clots observed in vivo following laser injury [9] can be replicated
in vitro with such devices [10].
Here we continue the development of microﬂuidic assay metrics
found previously [11] and extend thesemetrics to examine two ADP an-
tagonists and validate this assay for detection of anti-platelet therapies
through Receiver-Operator Characteristic (ROC) analysis. For ﬂow as-
says to become a relevant clinical tool a large cohort of healthy donors
must be tested with respect to response to antiplatelet agents. Toward
that goal, we tested healthy subject platelet function with 38 donors
and 66 independent blood draws (2 combined studies) after ex vivo ad-
dition of ASA.While coagulation assays can rely on stable pooled plasma
for calibration, live platelet function assays have no available standard
to calibrate the assay. We sought to deﬁne a self-normalized parameter,
the R-value, to score the accumulation of platelets on the surface for a
single blood sample test without reference to a prior test value or cali-
bration ﬂuid.
Materials and Methods
Blood Collection, Labeling, and Antiplatelet Agents
Blood was collected via venipuncture from 11 healthy subjects
who self-reported as non-smoking, free of oral medication, and
abstained from alcohol 48 hr prior to donation. All subjects were
free from illness or bleeding disorders. Blood samples were drawn
into H-D-Phe-Pro-Arg-chloromethylketone (100 μM PPACK ﬁnal
concentration, Haematologic Technologies). All volunteers provided
informed consent in accordancewith IRB approval and the Declaration of
Helsinki. Whole blood was treated with Phycoerythrin (PE) Mouse Anti-
Human CD61 (αIIbβ3) antibody (BD Biosciences) in a ratio of (1:50)
7 min prior to perfusion. This antibody has no effect on platelet αIIbβ3
function in the assay. PPACK-treated whole blood was perfused through
the devicewithin 25 min of phlebotomy. Bloodwas incubatedwith vehi-
cle (0.1% DMSO ﬁnal concentration) or indicated concentrations of ASA,
2MeSAMP, MRS 2179, or combined 2MeSAMP and MRS 2179 20 min
prior to the assay. This time scale is consistent with previous studies
done with these compounds [11–13]. Acetylsalicylic acid (ASA, Sigma
Aldrich) was dissolved in DMSO at 500 mM, 2-methylthioadenosine
5′-monophosphate triethylammonium salt hydrate (2MeSAMP, Sigma
Aldrich) was dissolved in HEPES buffered saline (HBS, 20 mM HEPES,
160 mM NaCl, pH 7.5) at 1 mM/L, and 2'-deoxy-N6-methyladenosine
3', 5'-bisphosphate ammonium salt (MRS 2179, Tocris Bioscience) at
0.1 mM in HBS. A dilution of ASA was then made to the desired ﬁnal
concentration in HBS within 1 h of the test. Final concentrations of
antiplatelet therapies used were: 500 μM ASA, 100 μM 2MeSAMP,
and 10 μM MRS 2179, well in excess of their IC50's in the assay of
10-20 μM ASA, 2.56 μM 2MeSAMP, and 0.23 μM MRS 2179 [11,13].
Antiplatelet agent concentrations were used well in excess of their
respective IC50 values to completely antagonize ADP receptors or
abate COX-1 derived TXA2.
Microﬂuidic Devices and Real Time Platelet Deposition Imaging
Microﬂuidic devices were fabricated in polydimethylsiloxane
(PDMS, Sylgard 184, Ellsworth Adhesives) according to previously
described techniques [11,13]. The microﬂuidic device has 8 parallel
channels (250 μm wide by 60 μm high) that converge to a common
outlet (Fig. 1A). The device was fed by 8 distinct wells, with perfusion
achieved by withdrawal into a single syringe pump (Harvard Appara-
tus). The channels run perpendicularly over a 250 μm long stripe ofpatterned equineﬁbrillar collagen type 1 (Chronopar, Chronolog). Chan-
nels were spaced in close proximity to allow for all channels to be im-
aged simultaneously with a 2X objective lens using an inverted
microscope (IX81, Olympus America Inc) equipped with a CCD camera
(ORCA-ER, Hamamatsu). A custom stage insert held 3 microﬂuidic
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vals. Prior to microﬂuidic assay, all channels were blockedwith 0.5% bo-
vine serum albumin (BSA) in HBS buffer. Blood samples were perfused
at venous wall shear rate of 200 s-1 for 5 min (2 μL/min per channel).
Platelet Accumulation Analysis
Background corrected ﬂuorescence values were measured using
MATLAB (MathWorks) as previously described [13]. Brieﬂy, all eight
platelet deposits on a single microﬂuidic device were identiﬁed and
corrected with their corresponding background regions downstream of
each platelet deposit by a customMATLAB script. To calculate overall per-
cent inhibition after a 300 s perfusion, ﬂuorescence values were normal-
ized to each donor's control platelet adhesion to collagen (FI300s(Drug)/
FI300s). Additionally, an R-value for ASA (RCOX) was deﬁned as a ratio of
platelet deposition rates that normalized the late stage platelet deposi-
tion rate (F'300-150s) to early stage deposition rate (F'150-60s) for all
ex vivo ASA additions, as previously established [11]. The RCOX value is
an internal intradonor standard to score secondary aggregation due to
TXA2 secretion,with values of RCOX N 1 indicatingwhen secondary plate-
let aggregation was prominent and RCOX b 1 when secondary aggrega-
tion was not detected (Fig. 1C). In a previous work [11], a dose
dependent decrease in the rate of secondary platelet aggregation was
found with increasing ex vivo ASA concentrations whereas the primary
platelet deposition rate on collagen was unaffected by ASA. We now
deﬁne an additional intradonor normalization metric RP2Y as a ratio of
platelet deposition rates normalizing late stage secondary platelet aggre-
gation rate due to ADP release (F'300-105s) to earlier stage platelet deposi-
tion rate (F'105-60s) (Fig. 1D). The temporal onset for RP2Y was based on
previous work [12] establishing that the effect of ADP antagonism oc-
curred after 100 sec, as was further conﬁrmed in kinetic traces for ADP
antagonists for the 11 donors in the present study (Fig. 1B).
Finally, sensitivity and speciﬁcity for detection of ASA, 2MeSAMP, or
MRS 2179 was found through Receiver Operator Characteristic (ROC)
analysis [14]. ROC curves were generated to detect the presence of
each drug in the microﬂuidic assay through evaluation of true positive
and false positive fractions and the area under the curve (AUC) [14].
In this analysis, for each antiplatelet therapy tested, ROC curves were
generated comparing 10 average R-values, one from each of the 10 sub-
jects with no ex vivo inhibition to 10 average measurements of the R-
value for each anti-platelet drug.
Results
Ex vivo testing of anti-platelet agents occurred in duplicate on 3 sep-
arate microﬂuidic devices run simultaneously. For 11 subjects, a total of
432 individual thrombi were formed under ﬂow on collagen, resulting
in 108 events each for 3 conditions (control, 2MeSAMP, and MRS
2179), 60 events for ex vivo ASA addition, and 48 events for ex vivo ad-
dition of 2MeSAMP and MRS 2179. Statistical analysis was conducted to
evaluate intradonor variations for duplicate control conditions on a sin-
gle microﬂuidic device and 3 devices run simultaneously (6 conditions).
Total platelet accumulation (FI300s) and secondary aggregation [RCOX(0)]
values for whole blood perfusion with vehicle buffer were tabulated
from 11 blood samples and the coefﬁcient of variation for each donor
deﬁned as standard deviation/mean was found (Supplemental
Table S1, S2). Coefﬁcients of variation for FI300s ranged from 5.3% to
35.8% (mean = 13.1%) for replicate control channels on a single device
while values varied from 5.3% to 24.4% for triplicate microﬂuidic testing
(mean = 16.3%). For RCOX (0), coefﬁcient of variation values were
all b 20% for a single microﬂuidic device or triplicate device testing
with the exception of donor 4 and donor 10. In 3 comparisons evaluat-
ing ex vivo ASA efﬁcacy (Fig. 5), prior supplementary data for 28 indi-
viduals [11] obtained in the same manner as this study was combined
with data from 10 subjects from this work. Only 1 subject partook in
both ASA studies.Platelets adhere substantially to the localized collagen surface with-
in 1 minute and subsequent secondary platelet accumulation via
platelet-platelet interactions over the 300 s perfusion time has been
established in previous studies [12,13]. Growth in platelet coverage oc-
curs in two dimensions on the collagen surface between 60 -105 sec.
After 105 sec, the thrombus growth continues in the third dimension
and becomes signiﬁcant under ﬂow due to secondary platelet-platelet
aggregation mediated by soluble agonists such as ADP and TXA2 at
approximately 105 sec and 150 sec, respectively.
Platelet Inhibition by ASA, 2MeSAMP, and MRS 2179
Platelet adhesion and subsequent secondary platelet aggregation
were signiﬁcantly reduced upon ex vivo addition of ASA, 2MeSAMP, or
MRS 2179 (Fig. 1B). Using RCOX or RP2Y (Fig. 1C, D), 8 out of 10 subjects
displayed signiﬁcant secondary platelet aggregation [R(0 drug) N 1]
before ex vivo drug addition (Fig. 2A-C). In contrast, 9 out of 10 subjects
had RCOX b 1 upon ex vivo treatment with ASA (Fig. 2A). Furthermore, 9
out of 10 subjects had RP2Y b 1with ex vivo 2MeSAMP addition, demon-
strating that most subjects had secondary platelet aggregation and pri-
mary platelet deposition that was sensitive to P2Y12 antagonism
(Fig. 2B). RP2Y was less reliable in scoring MRS 2179 inhibition of P2Y1
with only 6 out of 10 subjects having RP2Y b 1 (Fig. 2C), in part (ironical-
ly) due to the high potency of MRS 2179 in reducing Ca2+ mobilization
through P2Y1 signaling. Hence MRS 2179 drastically reduces primary
platelet deposition in comparison to 2MeSAMP, thus the associated dif-
ﬁculty of taking a ratio of two small numbers since both primary depo-
sition and secondary aggregation rate were affected by MRS 2179.
ROC curves were generated to examine the inhibitory effects of ASA,
2MeSAMP, and MRS 2179 in this assay (Fig. 2D-F). In comparing 10
measurements of RCOX(0) (true full COX-1 activity, full P2Y12 and
P2Y1 function) to 10 measurements of RCOX (500 μM ASA) (true full
COX-1 inhibition), the ROC curve had an AUC of 0.874 (Fig. 2D). Com-
parison of 10 RP2Y values at baseline to 10 RP2Y(100 μM 2MeSAMP)
(true full P2Y12 antagonism) gave an ROC curve AUC of 0.966
(Fig. 2E). Finally, in comparing the same 10 baseline RP2Y values to
RP2Y(10 μMMRS 2179) an ROC curve AUC of 0.889was obtained. Calcu-
lated ROC AUC values indicate excellent diagnostic discrimination
between populations upon ex vivo treatment with ASA, 2MeSAMP, or
MRS 2179. ASA, 2MeSAMP, and MRS 2179 all decreased total platelet
accumulation at 300 sec when normalized against baseline collagen re-
sponse reaching statistical signiﬁcance for the entire cohort (p b 0.01,
n = 10 subjects) and each antiplatelet agent (Fig. 3). The % inhibition
of platelet function was much greater for 2MeSAMP and MRS 2179
than ASA. However, the effect of ex vivo 2 MeSAMP and MRS 2179
were not statistically different from each other. While the % inhibition
is very useful for measuring drug potency following ex vivo drug addi-
tion, it requires reference to a separate untreated blood sample which
may not necessarily be available clinically with patients. In contrast,
the R-value is self-normalized and can be used for a single blood sample
obtained from a patient without the need to reference to a prior blood
test to obtain % inhibition.
Platelet Inhibition by Combined 2MeSAMP and MRS 2179 ex vivo Addition
To investigate the effects of combined P2Y1 and P2Y12 inhibition by
MRS 2179 and 2MeSAMP respectively, 7 of the 10 subjects from the
above study of ex vivo addition of either P2Y1, P2Y12, or COX-1 inhibitor
alone were re-enrolled along with new subject #11. Platelet ﬂuores-
cence traces over time representing thrombus buildup during the
microﬂuidic assay were reduced in the case of combined P2Y1 and
P2Y12 inhibition of platelet function in comparison to ex vivo P2Y1 or
P2Y12 inhibition alone (Fig. 4A). UsingMRS 2179 and 2MeSAMP togeth-
er, both primary deposition rate and secondary aggregation rates were
strongly reduced, compared to control or whenMRS 2179 or 2MeSAMP
were used individually (Fig. 4A).
Fig. 2.Microﬂuidic assay sensitivity and speciﬁcity of RCOX and RP2Y to detect inhibition of primary platelet adhesion or secondary platelet aggregation. (A), Rcox for ex vivo ASA addition.
(B), RP2Y for ex vivo 2MeSAMP addition. (C), RP2Y for ex vivo MRS 2179 addition. (D) ROC curve for detection of ex vivo ASA addition. (E), ROC curve for detection of ex vivo 2MeSAMP
addition. (F), ROC curve for detection of ex vivoMRS 2179 addition. Error bars indicate standard deviation from 6measurements of RCOX or RP2Y for each donor. Dashed lines are 95% con-
ﬁdence intervals.
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reduced total platelet accumulation at 300 secwhennormalized against
controlled platelet response to collagen (Fig. 4B). The platelet mass at
the end of 300 sec due to combined P2Y1 and P2Y12 inhibition was sig-
niﬁcantly smaller than the platelet masses due to single P2Y1 or P2Y12
inhibition (p b 0.001, n = 8 subjects) (Fig. 4B). Because the primary
deposition rate was so strongly attenuated, RP2Y was not suited to
score combined P2Y1 and P2Y12 inhibition (Fig. 4C). This is due to the
high efﬁcacy of combined MRS 2179 and 2MeSAMP treatment on the
primary platelet deposition rate on collagen in this microﬂuidic throm-
bosis model. The primary deposition rate becomes exceedingly low
once ADP is completely attenuated under ﬂow conditions by knocking
out both P2Y12 and P2Y1 signaling pathways. ADP is a potentmodulator
of platelet recruitment to the initial monolayer of platelets adherent to
collagen. The R-value was originally intended to score secondaryFig. 3.Effect of ex vivoASA, 2MeSAMP,MRS2179 onﬁnal platelet aggregate size normalized
by baseline platelet aggregate size formed over collagen. Ex vivo addition of ASA, 2MeSAMP,
MRS 2179 resulted in smaller ﬁnal platelet aggregate size compared to response measured
with no drug (p b 0.01, n = 10 donors).aggregation, hence the difﬁculties in using RP2Y to detect a ratio of plate-
let deposition rates over the two temporal ranges.Statistics of Platelet Phenotyping with Microﬂuidics Using ASA
Finally, we incorporate and quantify historical supplementary data
from a previous work [11] into this continuing study with intent to
show the full distribution of microﬂuidic platelet assay metrics (total
platelet accumulation, primary and secondary platelet deposition
rates, RCOX). Distribution of these metrics is optimal with maximum
data in assessing the capabilities of this microﬂuidic assay to detect
ex vivo addition of ASA.
Microﬂuidic phenotyping of 37 donors, 10 from the current study
and 28 fromaprevious study [11] showed a broaddistributionof prima-
ry platelet deposition rates on collagen with no ex vivo drug treatment
(Fig. 5A). Late stage secondary platelet aggregation also distributed
broadly (Fig. 5A). Binning of total platelet accumulation showed varied
inter-subject response to collagen with FI300s values ranging from 2,000
to 16,000 (Fig. 5B). Interestingly, the 10 healthy subjects from this study
exhibited FI300s values all below 6000 while the larger unique subset of
28 subjects from the previous study showed a wider range of FI300s
values. Gaussian-like distribution of RCOX(0) values centered above 1 in-
dicated that RCOX was a robust measurement of secondary aggregation
response in untreated whole blood (Fig. 5C). The use of RCOX = 1 as
the decision value was previously reported as the microﬂuidic assay
for detection of in vivo and ex vivo ASA had high discrimination (high
true positive rate with low false positive rate) at this anchoring point
[11]. In a total of 66 determinations of RCOX(0), 52 measurements
were above the RCOX = 1 cutoff demonstrating a majority of donors
had a strong secondary aggregation response in the assay. Observation
of 14 values of RCOX b 1 indicate some donors lack detectable secondary
aggregation by this assay, a phenomena potentially attributable to low
Fig. 4. Effect of combined ex vivo addition of 2MeSAMP andMRS 2179 on platelet function
in comparison to ex vivo addition of 2MeSAMP or MRS 2179 alone. (A) Platelet ﬂuores-
cence dynamics over time in the presence of ex vivo 2MeSAMP, MRS 2179, or combined
2MeSAMP and MRS 2179. (B) Ex vivo addition of 2MeSAMP and MRS 2179 reduced
ﬁnal thrombus size more signiﬁcantly than 2MeSAMP or MRS 2179 treatment alone
when normalized against ﬁnal control thrombus size over collagen (p b 0.01, n = 8 do-
nors). (C) RP2Y for combined ex vivo 2MeSAMPandMRS 2179 addition. Error bars indicate
standard deviation from 6 measurements of RP2Y for each donor.
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platelet deposit [12]. In contrast, with 500 μM ASA added ex vivo, 49 of
66 determinations of RCOX b 1 demonstrated most subjects hadplatelets that were sensitive to ASA inhibition of platelet TXA2
(Fig. 5C). The 17 determinations of RCOX where RCOX N 1 with 500 μM
ASA added ex vivo could be due to non COX-1 mediated ASA effects
on platelets when they are activated by collagen with autocrinic ADP
present [15]. Such blood samples may be worthy of further study with
respect to the phenotype of functional insensitivity to ASA despite
COX-1 acetylation. A notable left shift of the distribution away from
RCOX(0) was evident for the 66 determinations of RCOX(500 μM ASA)
(Fig. 5C).
Discussion
We demonstrated the utility of an 8-channel microﬂuidic device to
assess various anti-platelet agents on platelet function. We extended
from a previous study [11] the RCOX value, a normalizedmetric to detect
reduction in secondary aggregation due to ex vivo ASA addition
(Fig. 1C). We now deﬁne RP2Y a ratio of secondary platelet aggregation
rate to primary platelet deposition rate (with a different temporal pro-
ﬁle than RCOX) to quantify P2Y1 and P2Y12 antagonists (Fig. 2). Examina-
tion of RP2Y and ROC curve testing establish 2MeSAMP andMRS 2179 as
potent anti-platelet drugs that target initial platelet adhesion to colla-
gen and the secondary wave of platelet recruitment by attenuating
the autocrine ADP pathway (Fig. 6).
The effect of ASA on secondary platelet-platelet interactions has
been well characterized in platelet aggregometry [16]. Under ﬂow,
ADP and TXA2 are complex and interacting modulators since both can
become elevated in a concentration boundary layer [12]. Additionally,
RP2Y was shown to be unsuited for scoring the potency of combined
P2Y1 and P2Y12 antagonism of platelet function because primary depo-
sition rate was so strongly inhibited in this microﬂuidic thrombosis
model. Measured platelet ﬂuorescence traces and normalization of
ﬁnal platelet mass against control platelet masses formed over collagen
for 8 healthy donors showed ex vivo dual treatment with P2Y12 and
P2Y1 inhibitors to be signiﬁcantly more potent than single ex vivo
P2Y1 or P2Y12 antagonism (Fig. 4).
We report ﬁndings with some similarities and differences to the
prior ﬂow studies of Lucitt et al. [17] and Menolicchio et al. [18]. Lucitt
et al. found no effect on the rate of platelet coverage of the collagen sur-
face with in vitro ASA addition at 1500 s-1. However, percent surface
coverage may be a less sensitive measure of secondary aggregation
which also increases the height of the deposit. Menolicchio et al. also re-
ported a limited reduction of platelet aggregate growth above the layer
of platelets adherent to collagen with in vitro addition ASA at 1500 s-1.
Since there was no thrombin/ﬁbrin generation allowed in Lucitt [17]
who used 300 ATU hirudin or Menolicchio [18] who used 68 USP hepa-
rin, arterial shear rates of 1500 s-1 may limit the detection of ASA action
because thrombin/ﬁbrin dramatically stabilize the platelet deposit at ar-
terial conditions [7]. As a deposit grows in height in a ﬂow channel, the
shear rates become quite high during a constantﬂow rate perfusion and
embolization is likely, especially at an initial arterial wall shear rate,
with or without ﬁbrin present [7]. At the venous shear rate used with
antiplatelet agents in the present study, partially occlusive deposits
formed in the absence of thrombin/ﬁbrin are more reliably measured
since there is no embolization, even under constant ﬂow conditions. In
prior work, we have shown that the IC50 of ASA measured at venous
shear rates was quite similar to that measured at arterial shear rates
[11]. In addition, the IC50 of 2MeSAMP and MRS 2179 at venous shear
rates were also on the same order of magnitude to that found at arterial
shear rates (1000 s-1) (Supplemental Fig. S3).
Lucitt et al. also reported an effect of in vitro 2MeSAMP on initial
platelet recruitment on collagen delaying the time to reach 2.5% platelet
surface coverage to 56 sec as compared to 33 sec for the control case in
an 8 min assay at 1500 s-1. Lucitt et al. found that in vitro ASA had no
effect on this initial stage of platelet adhesion. We report ﬁndings con-
sistentwith Lucitt et al. but at 200 s-1.We found that ASA does not affect
primary platelet deposition to collagen (F'150-60s), while 2MeSAMP and
Fig. 5. Distribution of microﬂuidic metrics in the assessment of platelet adhesion to collagen and ASA's inhibition on platelet function under ﬂow. (A), Binning of primary and secondary
platelet deposition rates. (B), Binning ofﬁnal platelet accumulation asmeasured by platelet ﬂuorescence at t = 300 s (FI300s). (C), Binning of RCOX values in assessment of the effect of ASA
on secondary platelet aggregation in the microﬂuidic perfusion assay.
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more signiﬁcantly affects secondary platelet aggregation (F'300-105s) re-
quiring RP2Y as a new internally normalizedmetric to characterize plate-
let response to ADP antagonists under ﬂow. ADP antagonists were found
to inhibit platelet function by ~105 sec as compared to ~150 sec due to
ASA inhibition of TXA2 release. Also, Lucitt et al. determined 2MeSAMP
signiﬁcantly reduced the rate of platelet aggregation formation on colla-
gen by impairing recruitment of additional platelets. Menolicchio et al.
reportmarked reduction of platelet aggregation above the initial platelet
surface on collagen due to in vitro addition of 2MeSAMP. Both report
these results at 1500 s-1. This is consistent with our ﬁndings at 200 s-1
with RP2Y and ROC curves detecting signiﬁcant impairment of secondary
platelet aggregation due to both ADP antagonists tested.
Monitoring of P2Y12 inhibition by clopidogrel or other P2Y12 antag-
onists can be achieved through assays such as vasodilator-stimulated
phosphoprotein phosphorylation (VASP), turbidometric platelet
aggregometry, and the VerifyNow P2Y12 test. Although platelet
aggregometry remains the gold standard for platelet function testing,
several disadvantages exist such as poor reproducibility, high sample
volume, and complex sample preparation [20]. Turbidometric platelet
aggregometry testinguses ADP induced platelet aggregation tomeasure
the effect of clopidogrel. However, ADP can illicit platelet aggregation
through P2Y1 while VASP requires ﬂow cytometry and an experiencedtechnician [20]. Point of care assays are especially advantageous in clin-
ical settings as they enable immediate decisionmaking for dosing of an-
tiplatelet drugs. The VerﬁyNOWP2Y12 is the only device thatmeets the
various constraints to be considered a point of care assay. Interestingly,
in comparing the clinical utility of this microﬂuidic assay to the
VerifyNowP2Y12 system, ROC curve AUC valueswere strikingly similar.
A ROC curve value of 0.929 was found in the assessment of the
VerifyNow P2Y12 assay to detect antiplatelet effects during clopidogrel
therapy, comparable to the 0.966 value found for 2MeSAMP in this
study [21].
Often, microﬂuidic chambers utilize a single ﬂow path comprised of
a millimeter length collagen coated cover slip or capillary tube enabling
platelets to tether, activate, and re-adhere along the entire length [17].
With such long zones available for adhesion, the platelet coverage is
often a function of distance along the collagen. The current microﬂuidic
injury model exposes platelets to a narrow 250 μm long collagen strip
with no dependency on distance down the "injury" site as the image
capture zone is the entire prothrombotic surface. Furthermore, the
type of collagen used as the adhesive substrate impacts platelet-
surface interactions. Previous reports utilize bovine soluble collagen
type I, porcine type I collagen, or equine tendon ﬁbrillar type I collagen
[7,18,22]. The equine ﬁbrillar type I collagen used in this study is a thor-
oughly established prothrombogenic surface as a recent study
Fig. 6. Effect of P2Y1, P2Y12 antagonists and ASA on primary platelet adhesion to collagen
and secondary platelet aggregation due to ADP and thromboxane autocrine signaling.
COX-1 inhibitor ASA reduced secondary aggregation between 150 and 300 s without an
effect on primary platelet deposition to collagen from 60 to 150 s. 2MeSAMP and MRS
2179 reduced primary deposition between 60 and 105 s and secondary platelet aggrega-
tion between 105 and 300 s. Time intervals marked are indicators for RCOX and RP2Y, 60 -
150 sec & 150 sec - 300 sec and 60 - 105 sec & 105 sec - 300 sec respectively. X-axis is
not to scale.
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ﬂow assays for n = 104 healthy donors [23].
Several previous ﬂow systems have been examined for the detec-
tion of P2Y1, P2Y12 antagonists and COX-1 effects under various shear
rates [17,18,22]. However, distinct in our studies are the eight channels
comprising this single microﬂuidic device capable of performing dose-
response experiments for 8 different concentrations on a single anti-
platelet agent or high throughput examination of three antiplatelet
agents in duplicatewith simultaneous testingacross three devices. Single
channel platelet functionmeasurementsmake dose response testing and
high replicate testing of multiple drugs particularly cumbersome. Dose
dependent antiplatelet therapy testing on platelet function is crucial in
narrowing the therapeuticwindow for these drugs towards personalized
medicine in a clinical setting.
While antiplatelet agents are used for the prevention of arterial
thrombosis, the monitoring of antiplatelet agents in anticoagulated
whole blood (that lacks ﬁbrin stabilization) is perhaps most precisely
detected at venous shear rate, especially when constant ﬂowrate perfu-
sion is used. The action of antiplatelet agents on thrombus buildup in
the presence of ﬁbrin generation at arterial shear rates remains an
area of active investigation. Such arterial thrombosis studies will bebest conducted under microﬂuidic conditions of constant pressure
drop (not constant ﬂow rate) where channel occlusion is a natural
and important endpoint to the experiment [7]. Further work would be
required to examine whether the presence of thrombin and ﬁbrin in
this microﬂuidic thrombosis model affects the inhibitory capabilities
of 2MeSAMP andMRS 2179 on platelet function and aswell as the com-
pounds' respective IC50 values at venous and arterial wall shear rates. A
constant pressure drop microﬂuidic thrombosis model at initial arterial
wall shear rates would bemore physiologically relevant. This could be a
future avenue to investigate the efﬁcacy of P2Y1 and P2Y12 inhibitors
over increasingly complex surface triggered prothrombogenic surfaces
such as tissue factor and collagen [6].
The 8-channel microﬂuidic phenotyping of anti-platelet therapies in
this study was able to reproduce the biochemical signaling pathways
and transport processes under which antiplatelet therapies must act.
Quantiﬁcation through deposition rates, total platelet ﬂuorescence and
the all encompassing R value self-normalizes donors without requiring
donor speciﬁc measurements of vWF levels, platelet count, and
hemoatocrit. However, quantiﬁcation of secondary platelet aggregation
using RP2Y or RCOX has not been tested with patients on clopidogrel or
combined clopidogrel and aspirin regiments. Translation of these values
to quantify patients treated for coronary heart disease remains an area
of future study. This work represents another step towards a functional
high throughput point of care platelet function assay to detect patient
speciﬁc response to various antiplatelet therapies.
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